|
Santen Pharmaceutical Co., Ltd. is a pharmaceutical company focused on the research, development, manufacturing, and sale of ophthalmic drugs and medical devices. The company operates as a single segment, offering prescription and over-the-counter eye medications, as well as advanced vision science products. Its business activities span Japan, China, Asia, Europe, the Middle East, Africa, and the Americas. Key subsidiaries include Santen Inc., Eyevance Pharmaceuticals, Advanced Vision Science, and InnFocus. The company serves patients and healthcare providers globally through a network of regional entities such as Santen Holdings EU B.V., Santen India Private Limited, and Santen Pharmaceutical Asia Pte. Ltd. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage santen.com/en |
| Sector Healthcare | IR page santen.com/en | |
|
Tags
ophthalmology, eye care, prescription drugs, over-the-counter drugs, medical devices, vision science, Santen Inc., Eyevance Pharmaceuticals, Advanced Vision Science, InnFocus, Santen Holdings EU B.V., Santen India Private Limited, Santen Pharmaceutical Asia Pte. Ltd., Santen Canada Inc., Santen Ventures, Santen Oy, Santen S.A.S., Santen GmbH, Santen SAS, Santen Italy S.r.l., Santen UK Limited, Santen Pharmaceutical Spain S.L., SANTEN LIMITED LIABILITY COMPANY, Santen Pharmaceutical Vietnam Co. Ltd., SANTEN (THAILAND) CO. LTD., SANTEN PHILIPPINES INC., SANTEN PHARMA MALAYSIA SDN. BHD., Santen Holdings U.S. Inc., Eyevance Pharmaceuticals Holdings Inc., Eyevance Pharmaceuticals LLC, Santen Pharmaceutical Co. Ltd., Santen Pharmaceutical (China) Co. Ltd., Santen Pharmaceutical (Suzhou) Co. Ltd., Chongqing Santen Kerui Pharmaceutical Co. Ltd., Santen Pharmaceutical (Hong Kong) Co. Ltd., Santen Pharmaceutical Korea Co. Ltd., Santen Pharmaceutical Taiwan Co. Ltd.
|
Press page santen.com/ja/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 562.116B |
| Market cap (USD) | $ 3.526B |
| P/E | 14.49 |
| PEG | — |
| P/BV | 1.85 |
| P/S | 1.89 |
| P/OCF | 11.32 |
| P/FCF | 15.61 |
| Dividend yield | 2.2% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 12.9% |
| ROI | 12.6% |
| ROIC | 12.8% |
| Profit margin | 12.8% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 42 |
| Quality score | 22.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.624B | 300.004B | 301.965B | 279.037B | 266.257B | 249.605B | 241.555B | 234.026B | 224.942B | 199.096B | 195.291B | 161.881B | 148.663B | 119.066B |
| Net profit | 37.369B | 36.256B | 26.642B | -14.948B | 27.218B | 6.83B | 23.618B | 31.954B | 35.247B | 23.061B | 53.373B | 22.57B | 17.109B | 16.52B |
| Free cash flow | 29.234B | 49.909B | 61.962B | 12.559B | 10.202B | 15.004B | 30.719B | 24.561B | — | — | — | — | — | — |
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share price | 1.789K | 1.416K | 1.538K | 1.225K | 1.225K | 1.524K | 1.859K | 1.65K | 1.716K | 1.614K | 1.69K | 1.752K | 915.92 | 4.447K |
| Price performance 12m | 0.26 | -0.08 | 0.26 | 0 | -0.2 | -0.18 | 0.13 | -0.04 | 0.06 | -0.05 | -0.04 | 0.91 | -0.79 | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (JPY) | — | 78.7B | 84.6B | 87B | 96B | 99.6B | 107B | 90.5B | 71.8B | 71.8B |
| ↳ YoY growth | +7.6% | +2.8% | +10.3% | +3.7% | +7.6% | -15.5% | -20.7% | >-0.01% | ||
| ↳ 5y CAGR | +6.4% | +1.4% | -3.8% | -5.7% | ||||||
| Cash and deposits (JPY) | 52.3B | 69.3B | 70.8B | 91.4B | 62.9B | 83B | 57.9B | 94.6B | 93B | 80.9B |
| Intangible assets (JPY) | — | 134B | 131B | 120B | 113B | 130B | 96.3B | 83.8B | 75.5B | 71.7B |
| Cash flow detail | ||||||||||
| Operating cash flow (JPY) | 10.8B | 42.8B | 32.9B | 39.9B | 38.8B | 46B | 37.1B | 72.6B | 60.9B | 43.5B |
| Purchases of property, plant and equipment (JPY) | — | -3.98B | -5.47B | -5.82B | -4.14B | -17.3B | -17.3B | -9.32B | -6.66B | -6.84B |
| Purchases of intangible assets (JPY) | — | -5.95B | -2.86B | -3.4B | -19.7B | -18.5B | -7.31B | -1.37B | -4.36B | -7.42B |
| Change in receivables (cash effect) (JPY) | — | -7.12B | -6.3B | -3.05B | -7.51B | -1.97B | -6.44B | 18.4B | 18.5B | 2.67B |
| Change in inventories (cash effect) (JPY) | — | -1.44B | -5B | -981M | -4.59B | 5.38B | -1.14B | -1.37B | -8.38B | -10B |
| Change in payables (cash effect) (JPY) | — | 5.7B | 2.45B | 717M | 4.95B | 2.49B | 3.69B | -2.38B | -4.41B | -4.44B |
| Dividends paid (cash effect) (JPY) | — | -10.6B | -10.6B | -10.4B | -11.2B | -12B | -12.6B | -11.9B | -12.1B | -12.6B |
| Share buybacks (cash effect) (JPY) | — | -1M | -14.1B | -22M | — | -12M | -26B | -17B | -37.9B | -32.8B |
| Interest paid (cash effect) (JPY) | — | -27M | -8M | -190M | -159M | -240M | -465M | -830M | -1.09B | -1.26B |
| Operating cash flow before change in receivables (JPY) | — | 50B | 39.2B | 43B | 46.3B | 48B | 43.6B | 54.3B | 42.4B | 40.8B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | — | 32.9B | 24.6B | 30.7B | 15B | 10.2B | 12.6B | 62B | 49.9B | 29.2B |
| Income detail | ||||||||||
| Research and development expense (JPY) | — | 24.4B | 23.8B | 23.3B | 24.1B | 26.4B | 28.3B | 25.4B | 24.1B | 26.2B |
| ↳ 5y CAGR | +3.0% | +1.3% | +0.7% | +1.7% | ||||||
| Total comprehensive income (JPY) | — | 40.7B | 29.5B | 20.2B | 15.4B | 38.6B | -5.7B | 40B | 29B | 55.5B |
| Comprehensive income to owners (JPY) | 15.9B | 40.6B | 29.5B | 22.2B | 15.6B | 38.7B | -5.66B | 40B | 29.3B | 55.4B |
| Reported | Jun 23, 2017 | Jun 25, 2019 | Jun 25, 2019 | Jun 24, 2020 | Jun 25, 2021 | Jun 27, 2023 | Jun 27, 2023 | Jun 25, 2024 | Jun 23, 2025 | Jun 18, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Santen Pharmaceutical Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| JPAN | 0.79% | 6,000 | $ 78.745K | Jun 30, 2026 |
| AVDS | 0.12% | 32,700 | $ 425.458K | Nov 16, 2026 |
| DFIS | 0.06% | 283,700 | $ 3.551M | Nov 12, 2026 |
| AVSD | 0.04% | 11,400 | $ 148.325K | Nov 16, 2026 |
| DFIC | 0.04% | 460,700 | $ 5.767M | Nov 12, 2026 |
| DFSI | 0.03% | 26,100 | $ 326.699K | Nov 12, 2026 |
| DXIV | 0.03% | 5,100 | $ 63.838K | Nov 12, 2026 |
| DFAX | 0.02% | 218,800 | $ 2.739M | Nov 12, 2026 |
| DFAI | 0.02% | 285,895 | $ 3.579M | Nov 12, 2026 |
| AVDE | 0.00% | 18,500 | $ 240.702K | Nov 16, 2026 |



























